Nandini Piramal's Impact on Piramal Pharma and Future Growth Potential

Nandini Piramal: A Driving Force in Piramal Pharma

Nandini Piramal is making waves in the pharmaceutical industry as the Executive Director of Piramal Enterprises Limited. Under her leadership, Piramal Pharma is positioned to reach revenues of USD 2 billion by 2030, driven by its contract development and manufacturing complex, along with its hospital generics and consumer healthcare segments.

Strategic Growth through Contract Development

Antique Stock Broking noted that Piramal Pharma is relying heavily on its Contract Development and Manufacturing Organization (CDMO) segment, notably its Antibody-Drug Conjugate (ADC) platform, to boost growth potential.

Nandini's Leadership and Achievements

• Played a pivotal role in selling Piramal Healthcare's branded generic-medicine business to Abbott Laboratories for a record 30x EBITDA.
• Oversees Human Resources and IT functions within the Piramal Group.
• Recognized among India's Most Powerful Women by Business Today (2020) and as a Young Global Leader by the World Economic Forum (2014).

About Nandini's Background

She holds an MBA from Stanford and a Bachelor’s (Hons.) in Politics, Philosophy, and Economics from Oxford University.

Nandini Piramal's Net Worth

While Nandini's net worth remains undisclosed, her father, Ajay Piramal, is among India's wealthiest billionaires, with a current net worth of USD 2.8 billion. The Piramal Group reported consolidated revenues of Rs 9087 crore for FY 2023.